Recurrent abdominal pain in paediatric patients

Recurrent abdominal pain is a common problem in the paediatric population. While functional abdominal pain accounts for the majority of cases, an organic cause for pain may be found in about 5% to 10% of children. Diagnostic evaluation depends on the clinical presentation and the presence of specific findings. Excessive testing should be avoided as this may increase parental anxiety and put the child through unnecessary stress.published_or_final_versio

Ultraviolet f→f emission and crystal field analysis for Er3+ in Cs2NaErCl6

Luminescence is reported from the 2I11/2 level of Er3+, in the cubic elpasolite lattices Cs2NaErCl6 and Cs2NaYCl6. Altogether, with the use of ultraviolet laser excitation, 11 transitions from 2I11/2 Γ7 (at 40 668 cm-1) to lower term multiplets have been observed and assigned. Transitions are also reported from the 2K13/2 Γ6 level at 32 613 cm-1. The absence of emission from 2P3/2 (at 31 367 cm-1) under the experimental conditions is rationalized. Up-conversion to 2H(2)9/2, which is not due to two-photon absorption, is reported for Cs2NaErCl6 under blue pulsed laser excitation. Trap emission from 2G9/2 defect sites has been observed under ultraviolet excitation. A preliminary investigation has been made of the electronic absorption spectra of Cs2NaErCl6 and 58 Kramers quartet and doublet levels have been assigned, with a further 18 levels uncertain. The energy-level fit to 58 levels with total degeneracy 180 has been performed with a mean deviation of 20.4 cm-1, which is improved to 16.8 cm-1 if an empirical correction to the diagonal reduced matrix element of U4 for the 2H(2) term is included. The average error is similar for the 18 uncertain levels (total degeneracy 52). A comparison is included with the energy-level parametrizations of other Er3+ systems.published_or_final_versio

Evidence of the influence of phonon density on Tm³⁺ upconversion luminescence in tellurite and germanate glasses

Author name used in this publication: C. L. MakAuthor name used in this publication: W. L. TsuiAuthor name used in this publication: K. H. Wong2001-2002 > Academic research: refereed > Publication in refereed journalVersion of RecordPublishe

4f-5d transitions of Pr3+ in elpasolite lattices

The 4f5d→4f2 emission spectra of Cs2MPrCl6 (M = Na,Li) and CS2NaYCl6:Pr3+ have been recorded at temperatures down to 10 K. The spectra of Pr3+ in the cubic host Cs2NaYCl6 are the most clearly resolved, and 15 transitions to terminal crystal field levels of symmetry representations Γ5g and Γ4g have been observed and assigned, thereby inferring that the symmetry representation of the lowest 4f5d crystal field level is Γ3u. Each transition is characterized by strong progressions in two totally symmetric vibrational modes. The relative displacement of the potential energy curves for the 4f2 and 4f5d crystal field levels, along the α1g internal mode coordinate, is small, being only about 5 pm. The 10-K ultraviolet absorption spectra of CS2NaYCl6:Pr3+ are assigned to transitions from the [3H4] Γ1g electronic ground state to terminal Γ4u crystal field levels of 4f5d. Nontotally symmetric gerade vibrational modes only provide minor intensity contributions. The large energy gap between the d-f emission and f-d absorption spectra of Pr3+ in the cubic elpasolite host is rationalized. The 8-K excitation spectra of Cs2NaPrCl6 and Cs2NaYCl6:Pr3+, excited by synchrotron radiation, show that the transitions to 4f5d fall into two groups. The energy levels and wave vectors of the (independent) 4f2 and 4f5d configurations of Pr3+ have been calculated using a model which includes spin-orbit coupling and crystal field and Coulomb interactions, as well as the configuration interaction of 4f2 with 4f6p. Using the eigenvector of the predominantly high-spin, lowest excited crystal field level of 4f5d, the emission intensities are reasonably well simulated. However, the refinement of the 4f2→4f5d absorption intensities requires a more detailed knowledge of the crystal field energy level scheme of 4f5d. The configuration interaction of 4f5d with 4f6s and 4f5g is discussed.published_or_final_versio

MRI vessel wall imaging and treatment of an aneurysm at the atlanto-axial segment of an aberrant vertebral artery

published_or_final_versio

PTHrP Induces Autocrine/Paracrine Proliferation of Bone Tumor Cells through Inhibition of Apoptosis

Giant Cell Tumor of Bone (GCT) is an aggressive skeletal tumor characterized by local bone destruction, high recurrence rates and metastatic potential. Previous work in our lab has shown that the neoplastic cell of GCT is a proliferating pre-osteoblastic stromal cell in which the transcription factor Runx2 plays a role in regulating protein expression. One of the proteins expressed by these cells is parathryroid hormone-related protein (PTHrP). The objectives of this study were to determine the role played by PTHrP in GCT of bone with a focus on cell proliferation and apoptosis. Primary stromal cell cultures from 5 patients with GCT of bone and one lung metastsis were used for cell-based experiments. Control cell lines included a renal cell carcinoma (RCC) cell line and a human fetal osteoblast cell line. Cells were exposed to optimized concentrations of a PTHrP neutralizing antibody and were analyzed with the use of cell proliferation and apoptosis assays including mitochondrial dehydrogenase assays, crystal violet assays, APO-1 ELISAs, caspase activity assays, flow cytometry and immunofluorescent immunohistochemistry. Neutralization of PTHrP in the cell environment inhibited cell proliferation in a consistent manner and induced apoptosis in the GCT stromal cells, with the exception of those obtained from a lung metastasis. Cell cycle progression was not significantly affected by PTHrP neutralization. These findings indicate that PTHrP plays an autocrine/paracrine neoplastic role in GCT by allowing the proliferating stromal cells to evade apoptosis, possibly through non-traditional caspase-independent pathways. Thus PTHrP neutralizing immunotherapy is an intriguing potential therapeutic strategy for this tumor

On Being Negative

This paper investigates the pragmatic expressions of negative evaluation (negativity) in two corpora: (i) comments posted online in response to newspaper opinion articles; and (ii) online reviews of movies, books and consumer products. We propose a taxonomy of linguistic resources that are deployed in the expression of negativity, with two broad groups at the top level of the taxonomy: resources from the lexicogrammar or from discourse semantics. We propose that rhetorical figures can be considered part of the discourse semantic resources used in the expression of negativity. Using our taxonomy as starting point, we carry out a corpus analysis, and focus on three phenomena: adverb + adjective combinations; rhetorical questions; and rhetorical figures. Although the analysis in this paper is corpus-assisted rather than corpus-driven, the final goal of our research is to make it quantitative, in extracting patterns and resources that can be detected automatically

Drug transport in brain via the cerebrospinal fluid

The human brain has no lymphatic system, but produces over a half-liter each day of cerebrospinal fluid. The cerebrospinal fluid is secreted at the choroid plexus and occupies the cavities of the four ventricles, as well as the cranial and spinal sub-arachnoid space. The cerebrospinal fluid moves over the surfaces of the brain and spinal cord and is rapidly absorbed into the general circulation. The choroid plexus forms the blood-cerebrospinal fluid barrier, and this barrier is functionally distinct from the brain microvascular endothelium, which forms the blood-brain barrier. Virtually all non-cellular substances in blood distribute into cerebrospinal fluid, and drug entry into cerebrospinal fluid is not an index of drug transport across the blood-brain barrier. Drug injected into the cerebrospinal fluid rapidly moves into the blood via bulk flow, but penetrates into brain tissue poorly owing to the limitations of diffusion. Drug transport into cerebrospinal fluid vs. brain interstitial fluid requires knowledge of the relative expression of transporters at the choroid plexus versus the brain microvascular endothelium

Receptor-Mediated Enhancement of Beta Adrenergic Drug Activity by Ascorbate In Vitro and In Vivo

RATIONALE: Previous in vitro research demonstrated that ascorbate enhances potency and duration of activity of agonists binding to alpha 1 adrenergic and histamine receptors. OBJECTIVES: Extending this work to beta 2 adrenergic systems in vitro and in vivo. METHODS: Ultraviolet spectroscopy was used to study ascorbate binding to adrenergic receptor preparations and peptides. Force transduction studies on acetylcholine-contracted trachealis preparations from pigs and guinea pigs measured the effect of ascorbate on relaxation due to submaximal doses of beta adrenergic agonists. The effect of inhaled albuterol with and without ascorbate was tested on horses with heaves and sheep with carbachol-induced bronchoconstriction. MEASUREMENTS: Binding constants for ascorbate binding to beta adrenergic receptor were derived from concentration-dependent spectral shifts. Dose- dependence curves were obtained for the relaxation of pre-contracted trachealis preparations due to beta agonists in the presence and absence of varied ascorbate. Tachyphylaxis and fade were also measured. Dose response curves were determined for the effect of albuterol plus-and-minus ascorbate on airway resistance in horses and sheep. MAIN RESULTS: Ascorbate binds to the beta 2 adrenergic receptor at physiological concentrations. The receptor recycles dehydroascorbate. Physiological and supra-physiological concentrations of ascorbate enhance submaximal epinephrine and isoproterenol relaxation of trachealis, producing a 3-10-fold increase in sensitivity, preventing tachyphylaxis, and reversing fade. In vivo, ascorbate improves albuterol's effect on heaves and produces a 10-fold enhancement of albuterol activity in "asthmatic" sheep. CONCLUSIONS: Ascorbate enhances beta-adrenergic activity via a novel receptor-mediated mechanism; increases potency and duration of beta adrenergic agonists effective in asthma and COPD; prevents tachyphylaxis; and reverses fade. These novel effects are probably caused by a novel mechanism involving phosphorylation of aminergic receptors and have clinical and drug-development applications

Surgery and postoperative radiotherapy a valid treatment for advanced oropharyngeal carcinoma

Since 1992 we have prospectively included all head and neck cancer patients in our health region in a departmental based register. Our hospital takes care of all head and neck cancer patients in our health region consisting of approximately 1 million people. In 1997, we evaluated the results of the treatment of oropharyngeal cancer in the 1992–1997 period. On the basis of this evaluation, we changed our treatment policy for tonsillar and base of tongue carcinoma. We first changed the treatment for the lesions with worst prognosis, i.e., those with T3–T4 carcinomas, from radiotherapy only, to radical surgery and postoperative radiotherapy. We have since that time increasingly also operated the smaller oropharyngeal carcinomas. The 2 years’ overall survival and disease-specific survival for all patients diagnosed in the 1992–1997 period was 56 and 63%, respectively. The results from a similar group of patients in the 6 years’ period from 2000 to 2005, after the change in treatment, have increased to 83 and 88%. When we looked at the subgroup of patients in the 2000–2005 period treated with surgery and postoperative radiotherapy, 45 out of 69 patients (65%) presenting with an oropharyngeal cancer were fit for operation. With radical surgery and postoperative radiation therapy, the 2 years overall survival is now 91%. The 2-year disease-specific survival is 96% and the locoregional control is 98%. This is a marked improvement as compared to radiotherapy alone and definitely competitive with modern radiochemotherapy